DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1970)

Hepatitis B Virus Vaccine | Epidemiology | Mature Markets Data

Hepatitis B Virus Vaccine | Epidemiology | Mature Markets Data

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

DRG Epidemiology's coverage of the Hepatitis B vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the  Hepatitis B vaccine for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology's  Hepatitis B  vaccine forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the  Hepatitis B  vaccine over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following  Hepatitis B  vaccine patient populations:

Vaccine eligible population Newly eligible for vaccine population Note: coverage may vary by country and region.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overview
        • HBV Vaccine Eligible Adolescent and Adult Population per 1,000 people in 2018 and 2038
        • HBV Vaccine Eligible Pediatric Population per 1,000 people in 2018 and 2038
        • Relative Sizes of the Contributing Factors to the Trend in Total Eligible Adolescents and Adults Population for the HBV Vaccine Over the Next 20 Years.
        • Relative Sizes of the Contributing Factors to the Trend in Total Eligible Pediatric Population for the HBV Vaccine Over the Next 20 Years.
    • Epidemiology Data
    • Methods
      • HBV Vaccine Eligible Population
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: October 2018
  • Author(s): Alison Isherwood, MSc, MRes, PhD
  • Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.

Purchase Report

Recent reports:
You may also be interested in: